• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genentech

< Previous 1 2 3 4 5 6 Next >
News headline image
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 15, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
June 07, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
May 29, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
May 21, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
May 16, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
April 18, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
April 17, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
April 15, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
February 25, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
February 16, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
February 01, 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
December 19, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
December 10, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
December 09, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
December 08, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
December 08, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
December 05, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development
November 21, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
October 27, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
October 18, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
October 13, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
October 12, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
October 11, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 11, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
October 10, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
October 04, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
October 02, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
September 06, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
September 01, 2023
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
August 23, 2023
From Genentech
Via Business Wire
Tickers RHHBY
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap